The Faces of Regulation Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act

OHE Briefing, No. 41, May 2006

24 Pages Posted: 27 Aug 2015

Date Written: May 1, 2006

Abstract

This Briefing discusses, inter alia, the role of the Office of Fair Trading (OFT) in competition cases affecting the pharmaceutical industry. It does so in the context of a discussion of “ex ante” versus “ex post”approaches to regulation. This refers to the balance of reliance in a market on competition, sector specific regulation, and general competition law to deliver efficient outcomes. It was written prior to the OFT decision announced 30 September 2005 to carry out a market study of the Pharmaceutical Price Regulation Scheme (PPRS) as part of its review of government procurement arrangements in key sectors of the economy. The OFT market study can be thought of as looking at the effectiveness of one element of regulation – the ex ante sector specific regulation undertaken by the Government – rather than at the balance of regulation between the Department of Health as buyer and of the OFT in its role as the agent of general competition law. The paper does not address the OFT market study of the PPRS. As with all OHE publications it was peer reviewed by its Editorial Board and by other experts in the field and is intended to be a contribution to research and to public policy making. It does not represent the views of the OHE or of its funding body the ABPI.

Suggested Citation

Mestre-Ferrandiz, Jorge, The Faces of Regulation Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act (May 1, 2006). OHE Briefing, No. 41, May 2006, Available at SSRN: https://ssrn.com/abstract=2641832

Jorge Mestre-Ferrandiz (Contact Author)

Office of Health Economics ( email )

12 Whitehall
London, SW1A 2DY
United Kingdom

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
17
Abstract Views
306
PlumX Metrics